February 04, 2022
Final Approval In Glumetza Antitrust Deal Gives Attys $50M

A California federal judge granted final approval of three settlements resolving direct buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug Glumetza, awarding $50 million in attorney fees to class counsel, less than half of the $112.8 million they had sought.

11 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Direct access to case information and documents.
All significant new filings across U.S. federal district courts, updated hourly on business days.
Full-text searches on all patent complaints in federal courts.
No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

In Re Glumetza Antitrust Litigation

Case Number:

Court:

Nature of Suit:

Multi Party Litigation:

Judge:

Firms

Companies

Sectors & Industries:

View recent docket activity

Coverage

Final Approval In Glumetza Antitrust Deal Gives Attys $50M

Parties

Stay ahead of the curve